Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus TACE in intermediate to advanced hepatocellular carcinoma (real-world)
ChiCTR2000040387Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of University of Science and Technology of China
- Start
- Nov 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of University of Science and Technology of China. Primary endpoint: Progression-free survival. Started Nov 2020; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2000040387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040387.